Peginterferon alfa-2b

Peginterferon alfa-2b
Clinical data
Trade names	PegIntron, Sylatron, ViraferonPeg, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a605030
License data	EU EMA: by INN;
Routes of; administration	Subcutaneous injection
ATC code	L03AB10 (WHO) L03AB60 (WHO);
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	22–60 hrs
Identifiers
	IUPAC name PEGylated human interferon alpha 2b;
CAS Number	215647-85-1 ;
IUPHAR/BPS	7462;
DrugBank	DB00022 ;
ChemSpider	none;
UNII	G8RGG88B68;
KEGG	D02745 ;
ChEMBL	ChEMBL1201561 ;
ECHA InfoCard	100.208.164
Chemical and physical data
Formula	C860H1353N229O255S9
Molar mass	19269.17 g·mol−1
	(what is this?) (verify)

Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects. Subcutaneous injection is the preferred delivery method.

Belonging to the alpha interferon family of medications, the molecule is PEGylated to prevent breakdown. Approval for medical use in the United States was granted in 2001. It is on the World Health Organization's List of Essential Medicines as a therapy for chronic hepatitis C.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.